208 related articles for article (PubMed ID: 15583696)
1. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.
Memon AA; Sorensen BS; Melgard P; Fokdal L; Thykjaer T; Nexo E
Br J Cancer; 2004 Dec; 91(12):2034-41. PubMed ID: 15583696
[TBL] [Abstract][Full Text] [Related]
2. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Memon AA; Sorensen SB; Nexo E
Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
[TBL] [Abstract][Full Text] [Related]
3. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer.
Nielsen TO; Borre M; Nexo E; Sorensen BS
BJU Int; 2015 Jan; 115(1):163-5. PubMed ID: 24467768
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.
Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M
Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707
[TBL] [Abstract][Full Text] [Related]
7. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
[TBL] [Abstract][Full Text] [Related]
8. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
11. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
[TBL] [Abstract][Full Text] [Related]
12. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP
Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208
[TBL] [Abstract][Full Text] [Related]
13. Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.
Nielsen TO; Friis-Hansen L; Poulsen SS; Federspiel B; Sorensen BS
PLoS One; 2014; 9(4):e94606. PubMed ID: 24728052
[TBL] [Abstract][Full Text] [Related]
14. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
[TBL] [Abstract][Full Text] [Related]
15. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
16. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
17. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
Lipponen P; Eskelinen M
Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
[TBL] [Abstract][Full Text] [Related]
18. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
[TBL] [Abstract][Full Text] [Related]
19. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
[TBL] [Abstract][Full Text] [Related]
20. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]